Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)

Sarepta Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $372.4 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 64.37% year-over-year to $372.4 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 5.34% YoY), while the FY2025 annual figure was $2.9 billion, up 72.1% from the prior year.
• Operating Expenses was $372.4 million for Q1 2026 at Sarepta Therapeutics, down from $854.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.0 billion in Q1 2025 to a low of $297.7 million in Q1 2022.
• Historically, Operating Expenses has averaged $466.7 million across 5 years, with a median of $391.6 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses jumped 176.11% in 2025, then tumbled 64.37% in 2026.
• A 5-year view of Operating Expenses shows it stood at $365.3 million in 2022, then advanced by 1.89% to $372.2 million in 2023, then soared by 33.47% to $496.7 million in 2024, then surged by 72.03% to $854.5 million in 2025, then plunged by 56.42% to $372.4 million in 2026.
• The last three Operating Expenses figures came in at $372.4 million (Q1 2026), $854.5 million (Q4 2025), and $502.7 million (Q3 2025), per Business Quant data.